Yulia Volchek

Sheba Medical Center — Israel

Medicine · Health Sciences

10h-index413citations66works0.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Myeloid Leukemia Treatments(33), Acute Myeloid Leukemia Research(24), Hematopoietic Stem Cell Transplantation(22), Acute Lymphoblastic Leukemia research(20), Chronic Lymphocytic Leukemia Research(17)

Publications66 total

Allogeneic hematopoietic stem cell transplantation for myelofibrosis; Patterns, treatment and outcome after relapse and long-term follow up.
Blood·2025Open Access
Favorable survival and tolerability of the GMALL protocol in adolescents and young adults with ALL: A single-center experience
Blood·2025Open Access
Phase 2 trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in diffuse large B-cell lymphoma: Updated analysis of waveline-007
Blood·2025Open Access
Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma
Blood·2024· 2 cited
Outcomes of Fedratinib in Routine Treatment of Ruxolitinib-Resistant or -Refractory Patients with Primary and Post-Polycythemia Vera or Essential Thrombocythemia Myelofibrosis: A Nationwide Retrospective Study
Acta Haematologica·2024· 2 cited
Phase 3 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in patients with essential thrombocythemia (ET).
Journal of Clinical Oncology·2024
BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study
Blood·2023· 6 cited
MPN-381 BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II Study
Clinical Lymphoma Myeloma & Leukemia·2023
POSTER: MPN-381 BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II Study
Clinical Lymphoma Myeloma & Leukemia·2023
S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY
HemaSphere·2023Open Access
BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study
Blood·2022· 3 cited
Evaluating Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated on the GMALL Protocol
Blood·2020
Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia
Oncotarget·2020· 8 citedOpen Access
PB2282 REASSESSING THE EFFICACY OF LOW DOSE RASBURICASE FOR MANAGEMENT OF TUMOR LYSIS SYNDROME IN HIGH RISK HEMATOLOGIC MALIGNANCIES
HemaSphere·2019Open Access
PF271 USING NEXT‐GENERATION SEQUENCING TO PREDICT RESPONSE TO SALVAGE CHEMOTHERAPY WITH HIGH DOSE CYTARABINE AND MITOXANTRONE IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PATIENTS
HemaSphere·2019Open Access
Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study
Clinical Lymphoma Myeloma & Leukemia·2018· 27 cited
Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors
Blood·2016· 7 cited
Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia
Oncotarget·2016· 12 citedOpen Access
A Nationwide Observational Study of Ponatinib in CML Patients Outside of Clinical Trials- The Israeli Experience
Clinical Lymphoma Myeloma & Leukemia·2016
A Nationwide Observational Study of the Israeli Experience with Ponatinib Outside Clinical Trials in Chronic Myeloid Leukemia
Blood·2015
page 1 of 4Next →

Frequent Co-authors

Arnon Nagler(39), Avichai Shimoni(37), Ronit Yerushalmi(33), Noga Shem‐Tov(30), Abraham Avigdor(10), Avital Rand(10), Ivetta Danylesko(8), Izhar Hardan(8), Maya Koren‐Michowitz(7), Raz Somech(6), Nira Varda‐Bloom(5), Drorit Merkel(5), David Lavie(5), Ninette Amariglio(5), Eran Tallis(4), Jonathan Canaani(4), Hannah Maayaan(4), Pia Raanani(3), Gabriel Heering(3), Meirav Kedmi(2)